Results: The incidence cohort consisted of 254 cases with 78% males and a mean age of 65.6 years. Forty-eight percent were Caucasian, with Asians 20%, Mediterraneans 18% and Africans 10%. Cirrhosis was present in 86% of patients. Chronic HCV infection (42%)

was the commonest cause of underlying liver disease, followed by alcohol (39%), chronic HBV infection (18%), and NAFLD (12%). Overall only 14% were diagnosed by biopsy. Diagnosis of HCC outside a screening program occurred in 54%. HCC diagnosed by screening were more likely to have early stage disease (BCLC 0 to B) than those diagnosed outside a screening program (52.5% vs. 9.5%, p < 0.0001). The age-standardized incidence rates (per 100,000 Australian Standard Population) for Melbourne were 8.05 in males and 2.12 in females, compared to Victorian incidence rates in 2011 of 5.2 and 1.2, respectively

(Victorian Cancer Registry 2012). Conclusion: In the first population-based incidence Small molecule library molecular weight study of HCC in Australia, we have shown that the incidence of HCC in Melbourne ICG-001 datasheet is higher than previously reported in Victoria. This has important implications for the allocation of healthcare resources. Hepatitis C and alcohol are the leading causes of HCC. Tumours diagnosed within surveillance programs had earlier stage disease, suggesting that increased uptake of surveillance may improve clinical outcomes. X ZHOU,1 K SHAW,1 L ALGIE,2 J FAWCETT,2 K STUART1 1Department of Gastroenterology and Hepatology Princess Alexandra Hospital, Brisbane, Australia, 2Liver Transplant Services, Princess Alexandra Hospital, Brisbane, Australia

Background: The Barcelona Clinic Liver Cancer (BCLC) staging system is the most widely used treatment algorithm for Hepatocellular Carcinoma (HCC). Patient performance status (PS) is a key component of the revised BCLC criteria. Patients with an ECOG status of ≥1 are categorised as BCLC Stage C irrespective of tumour size and number. Other HCC staging systems place more emphasis on the characteristics of the tumour than the health status of the patient in their treatment decision making process. Aims and methods: The aim of this study was to assess the influence of PS on treatment selection and overall survival in patients with BCLC Early Stage HCC. A retrospective review was conducted of all patients with 上海皓元医药股份有限公司 BCLC Early HCC who were treated with curative intent using radiofrequency ablation (RFA), surgical resection (SR) or liver transplantation (LT) at a single Australian liver transplant centre between January 2005 and June 2012. Early HCC was defined as a single tumour ≤6.5 cm or ≤3 tumours, none greater than 4.5 cm in maximum diameter with a total tumour diameter of ≤8 cm. Patients were divided into two groups based on their PS (ECOG 0–1; good performance group, ECOG ≥2 poor performance group). Demographic data, clinical and laboratory characteristics, treatment selection and overall survival were compared between the two groups.